Cytokinetics

Jiangsu Hengrui Pharmaceuticals has licensed its selective myosin blocker HRS-1893 to Delaware-based startup Braveheart Bio for $65 million upfront plus potential milestone payments exceeding $1 billion.

Aficamten, Cytokinetics' cardiac myosin inhibitor, met its primary endpoint in the Phase 3 MAPLE-HCM trial, demonstrating significant improvement in peak oxygen uptake in obstructive hypertrophic cardiomyopathy patients.

Neurocrine Biosciences, Madrigal Pharmaceuticals, and Vanda Therapeutics provided investors with key updates on their recent drug launches during Q1 earnings calls.

• Haya Therapeutics has raised $65 million in Series A funding to develop therapeutics targeting long non-coding RNAs in the previously dismissed "junk DNA" regions of the human genome. • The company's lead candidate, HTX-100, targets a long non-coding RNA called "Wisper" that plays a central role in non-obstructive hypertrophic cardiomyopathy, with clinical trials expected to begin soon. • Unlike competitors' approaches that focus on reducing heart contractions, Haya's technology aims to address the underlying disease mechanisms by suppressing fibrosis and reprogramming disease-driving cell states.

Cytokinetics will present five studies on aficamten at the upcoming ACC Scientific Session, including new data on its metabolism pathways through multiple CYP enzymes and the safety of combination therapy with disopyramide.

The global cardiomyopathy market is expected to grow at a CAGR of 6.13% from 2025-2035, driven by rising cardiovascular disease prevalence and innovative therapeutic developments.

Cytokinetics has commenced enrollment for the AMBER-HFpEF Phase 2 trial to assess CK-586 in patients with symptomatic heart failure with preserved ejection fraction (HFpEF).

Cytokinetics stopped the Phase 3 COURAGE-ALS trial of resedemtiv for amyotrophic lateral sclerosis (ALS) after a futility analysis showed no benefit over placebo.

Cytokinetics anticipates a pivotal year in 2025, focusing on the potential FDA approval and commercial launch of aficamten for obstructive hypertrophic cardiomyopathy (HCM) in the U.S.

Sanofi has acquired exclusive rights from Corxel Pharmaceuticals to develop and commercialize aficamten in Greater China for hypertrophic cardiomyopathy (HCM).